Thursday, July 9, 2026

Patent intelligence · US

US 11767355

Methods for modulating an immune response

granted A61KA61K2039/505A61K38/1774A61K38/2013
Status granted
Linked drugs 1
Pipeline programs 6
Years to expiry 17
Applicant portfolio 30
Patent details — US 11767355
Jurisdiction
US
Status
granted
Grant date
Sep 26, 2023
Expiration
Sep 21, 2043
Claims
28
CPC classes
A61K, A61K2039/505, A61K38/1774, A61K38/2013
View on Google Patents ↗

Quick answer

US 11767355 (Methods for modulating an immune response) is held by Cue Biopharma, Inc.. Status: granted. Granted Sep 26, 2023. Expires Sep 21, 2043 (17 years remaining) — relevant for patent-cliff and LOE planning.

Key facts

Grant date
Expiration
Claims
28
CPC classes
A61K, A61K2039/505, A61K38/1774, A61K38/2013, A61K39/3955, A61K47/644

More from Cue Biopharma, Inc.

Related pharmaceutical patents in our USPTO index.

  1. US 12421287

    T-cell modulatory multimeric polypeptides and methods of use thereof

    Cue Biopharma, Inc. · Expires Sep 18, 2045

    granted
  2. US 12257311

    Multimeric T-cell modulatory polypeptides and methods of use thereof

    Cue Biopharma, Inc. · Expires Mar 20, 2045

    granted
  3. US 12180258

    T-cell modulatory multimeric polypeptides and methods of use thereof

    Cue Biopharma, Inc. · Expires Dec 26, 2044

    granted
  4. US 12152061

    T-cell modulatory multimeric polypeptides and methods of use thereof

    Cue Biopharma, Inc. · Expires Nov 21, 2044

    granted
  5. US 12145973

    T-cell modulatory multimeric polypeptides and methods of use thereof

    Cue Biopharma, Inc. · Expires Nov 14, 2044

    granted
  6. US 12029782

    MHC class II T-cell modulatory multimeric polypeptides for treating type 1 diabetes mellitus (T1D) and methods of use thereof

    Cue Biopharma, Inc. · Expires Jul 4, 2044

    granted
  7. US 12006348

    T-cell modulatory multimeric polypeptide with conjugation sites and methods of use thereof

    Cue Biopharma, Inc. · Expires Jun 6, 2044

    granted
  8. US 11993641

    Methods for modulating an immune response

    Cue Biopharma, Inc. · Expires May 23, 2044

    granted

Frequently asked questions

What is US patent 11767355?

US 11767355 (Methods for modulating an immune response) is held by Cue Biopharma, Inc.. Status: granted. Granted Sep 26, 2023. Expires Sep 21, 2043 (17 years remaining) — relevant for patent-cliff and LOE planning.

Who owns US 11767355?

Cue Biopharma, Inc. is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 30 pharmaceutical patents for this assignee.

When does US 11767355 expire?

Our index shows an expiration date of Sep 21, 2043 (17 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.